Core Insights - Propanc Biopharma has filed a provisional patent application for a fully synthetic recombinant version of PRP, aimed at treating and preventing metastatic cancer from solid tumors [1][3] - The global metastatic cancer market is projected to reach $111 billion by 2027, indicating significant market potential for Propanc's innovations [1] - The synthetic version of trypsinogen and chymotrypsinogen, named Rec-PRP, offers advantages such as longer shelf life and suitability for distribution in regions lacking refrigeration [2] Company Developments - The recent patent application is the third filed in two months, enhancing the company's intellectual property portfolio as it prepares for national phase applications worldwide [3] - The company is focused on developing a platform technology that targets cancer stem cells, aiming to provide a treatment option with fewer side effects compared to standard therapies [4] - Propanc is also expanding its research into other therapeutic areas with significant unmet medical needs, indicating a strategic approach to long-term growth [3]
Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia
Globenewswire·2026-01-20 13:45